EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Current National Treatment Trends for Gastric Adenocarcinoma in the United States

Dominic J Vitello, Norah N Zaza, Kelly R Bates, Lauren M Janczewski, Gladys Rodriguez, David J Bentrem

Journal of Surgical Oncology · 2024-12 · 130 (8) · 1563-1572

DOI: 10.1002/jso.27863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 10.10.2024. Verfasst von Dominic J Vitello und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, This study was supported by National Institutes of Health (Grant 5R38CA245095); National Cancer Institute (Grant T32CA247801); Steven J. Stryker, MD Gastrointe…, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The treatment of gastric adenocarcinoma (GA) continues to evolve. While neoadjuvant chemotherapy (NAC) has demonstrated emerging benefit, the optimal treatment regimen, and sequence remain to be firmly established.

Methods

Patients with nonmetastatic GA who underwent resection were identified within the 2020 National Cancer Database. Patients were compared between the mutually exclusive treatment groups of NAC, neoadjuvant chemoradiotherapy (NCRT), adjuvant chemotherapy, adjuvant chemoradiotherapy (CRT), and surgery only. The primary endpoint was receipt of NAC or NCRT. Patients were 1‐to‐1 propensity score matched for receiving any neoadjuvant therapy. Multivariable logistic regression was used to identify predictors of receipt of any neoadjuvant therapy and receipt of any adjuvant therapy.

Results

Twenty‐five thousand and seventy‐three patients were included in the analysis. Patients were treated with NAC (25.0%), NCRT (31.4%), adjuvant chemotherapy (6.5%), adjuvant CRT (12.6%), and surgery only (24.5%). Compared to 2006−2011, patients diagnosed between 2012 and 2017 experienced the greatest increases in NAC (18.6% vs. 29.0%; p < 0.001) and NCRT (25.0% vs. 35.5%; p < 0.001). Median OS was 44.9 months. OS was longest for patients who received any neoadjuvant therapy compared to those receiving adjuvant or surgery only (51.0 vs. 42.4 vs. 38.0 months, respectively; p < 0.001). Patients who were Black, in the lowest income quartile or treated at lower volume facilities were less likely to receive NAT (all p < 0.001).

Conclusions

There has been significant acceleration in the use of neoadjuvant therapy for GA. Currently, NCRT followed by surgery are the most common treatment sequences in the United States. Additional trials are needed to further define the optimal treatment sequence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaNeoadjuvant TherapyHumansFemaleMaleUnited StatesMiddle AgedAgedChemotherapy, AdjuvantChemoradiotherapy, AdjuvantSurvival RateRetrospective StudiesGastrectomyFollow-Up Studies

Stichwörter der Autor:innen

adjuvant therapychemoradiotherapygastric adenocarcinomaneoadjuvant therapy

Autor:innen und Institutionen

  • Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Surgery, Jesse Brown Veterans Administration Medical Center, Chicago, Illinois, USA.
  • Department of Hematology and Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Förderung

  • NCI NIH HHS
  • This study was supported by National Institutes of Health (Grant 5R38CA245095); National Cancer Institute (Grant T32CA247801); Steven J. Stryker, MD Gastrointe…
  • National Institutes of Health

Zitieren

APA

Vitello, D. J., Zaza, N. N., Bates, K. R., Janczewski, L. M., Rodriguez, G., & Bentrem, D. J. (2024). Current National Treatment Trends for Gastric Adenocarcinoma in the United States. Journal of Surgical Oncology, 130(8), 1563-1572. https://doi.org/10.1002/jso.27863

Vancouver

Vitello DJ, Zaza NN, Bates KR, Janczewski LM, Rodriguez G, Bentrem DJ. Current National Treatment Trends for Gastric Adenocarcinoma in the United States. Journal of Surgical Oncology. 2024;130(8):1563-1572. doi:10.1002/jso.27863

BibTeX
@article{Vitello2024,
  author = {Vitello, Dominic J and Zaza, Norah N and Bates, Kelly R and Janczewski, Lauren M and Rodriguez, Gladys and Bentrem, David J},
  title = {Current National Treatment Trends for Gastric Adenocarcinoma in the United States},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  volume = {130},
  number = {8},
  pages = {1563--1572},
  doi = {10.1002/jso.27863}
}
Kostenlos starten →